S&P 500
7,401.00
+0.91%
Dow Jones
49,665.70
+0.19%
Nasdaq 100
29,241.00
+2.43%
Russell 2000
2,860.88
+0.82%
FTSE 100
10,263.70
+0.48%
Nikkei 225
63,767.70
+2.68%

Health and Healthcare

NASDAQ Changes Up Biotech Index Members & Weightings

Photo of Jon C. Ogg
By Jon C. Ogg Updated Published
Follow 24/7 Wall St. on Google
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Invalid Image
Index changes are generally speaking a fairly routine event.  They can also create underlying moves in the companies added and deleted from them as money management firms often buy and sell shares, as do exchange-traded funds, mutual funds, hedge funds, and speculators gaming index changes. The NASDAQ Biotechnology Index has announced some changes.  The biotech sector has seen its share of mergers, as well as a rise and fall in many underlying names in this volatile sector.These changes will become effective prior to the market open on Monday, May 21, 2012.

The following ten securities will be added to the Index: Cerus Corporation (Nasdaq: CERS), Celldex Therapeutics, Inc. (Nasdaq: CLDX), Amicus Therapeutics, Inc.(Nasdaq: FOLD), Infinity Pharmaceuticals, Inc. (Nasdaq: INFI), Jazz Pharmaceuticals plc (Nasdaq: JAZZ), Omeros Corporation (Nasdaq: OMER), Orexigen Therapeutics, Inc. (Nasdaq: OREX), Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), Raptor Pharmaceutical Corporation (Nasdaq: RPTP), and Trius Therapeutics, Inc. (Nasdaq: TSRX).

The following members will be booted from the NASDAQ Biotechnology Index: BioSante Pharmaceuticals, Inc. (Nasdaq: BPAX), China Biologic Products, Inc. (Nasdaq: CBPO), Columbia Laboratories, Inc. (Nasdaq: CBRX), Cardiome Pharma Corp (Nasdaq: CRME) and DURECT Corporation (Nasdaq: DRRX).

The NASDAQ Biotechnology Index tracks the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical and it is re-ranked twice a year (May/November).

The iShares Nasdaq Biotechnology (NASDAQ: IBB) ETF has more than $1.8 billion in assets and it aims to track the NASDAQ Biotechnology Index per its description.  SPDR S&P Biotech (AMEX: XBI) has more than $500 million in assets tracks the biotech members ranked by S&P, but there are some overlaps in the indexes. Market Vectors Biotech ETF (AMEX: BBH) has only just over $100 million in assets and tracks the  Market Vectors US Listed Biotech 25 Index.

JON C. OGG

Photo of Jon C. Ogg
About the Author Jon C. Ogg →

Jon Ogg has been a financial news analyst since 1997. Mr. Ogg set up one of the first audio squawk box services for traders called TTN, which he sold in 2003. He has previously worked as a licensed broker to some of the top U.S. and E.U. financial institutions, managed capital, and has raised private capital at the seed and venture stage. He has lived in Copenhagen, Denmark, as well as New York and Chicago, and he now lives in Houston, Texas. Jon received a Bachelor of Business Administration in finance at University of Houston in 1992. www.247wallst.com.

Continue Reading

The Top Biotech ETFs to Watch in 2020
Chris Lange |

The Top Biotech ETFs to Watch in 2020

On a company by company basis, investing in biotechs is somewhat tricky. However, there is an investment strategy that makes…

Top Biotech Stocks and ETFs: A Sector in Trouble or a Huge Bargain
Jon C. Ogg |

Top Biotech Stocks and ETFs: A Sector in Trouble or a Huge Bargain

24/7 Wall St. has looked over some of the biotech sector's laggards, and we have also looked over the top…

The Best Biotech ETFs to Buy Ahead of ASCO
Chris Lange |

The Best Biotech ETFs to Buy Ahead of ASCO

The 55th annual meeting of the American Society of Clinical Oncology (ASCO) is just around the corner. Biotech and pharmaceutical…

Trump’s Drug Price Comments Weigh on Biotech and Pharma ETFs and Shares
Jon C. Ogg |

Trump’s Drug Price Comments Weigh on Biotech and Pharma ETFs and Shares

Trump told Time that he wants to lower drug prices, a move that has hit the drug and biotech segments…

Jon C. Ogg |

ETF Folly: Biotech ETFs, Nothing but Confusion

Thinkstock24/7 Wall St. has always wondered about the confusing universe of biotech exchange-traded funds (ETFs). Biotech stocks can rise or…

Douglas A. McIntyre |

A Closer Look at Five Biotech ETFs

From BioHealth Investor For those investors not keen on spending countless hours pouring over financial statements and company profiles, not…

Lee Jackson |

Huge Biotech Index Rebalance Means Massive Buy Orders for These 4 Stocks

On the close Friday, the NYSE Arca Biotechnology Index is set for a rebalance. These four stocks that could see…

Jon C. Ogg |

BioHealth Business Daily, Major News Breaks (QCOR, DNDN, GERN, STEM, ASTM, CYTX, NBS, BTIM, PSTI, SVA, VVUS, OREX, ARNA, SNTS, GENZ, SNY, TEVA, AMGN, ACOR, CELG, HGSI, BIIB, GILD, EXAS, ZGEN, DYAX, IDXX, VPHM)

Biotech and BioHealth stocks are on the move today and there is more news in the emerging sector than there…

Jon C. Ogg |

BioHealth Business Daily (ALXA, ALKS, ALTH, DNDN, JNJ, GERN, GENZ, IMGN, JAZZ)

The world of biotech and biohealth is seeing a flurry of news today.  This is bringing on many winners and…

Top Gaining Stocks

Akamai
AKAM • Vol: 21,556,944
Micron Technology
MU • Vol: 65,135,624
Intel
INTC • Vol: 227,504,426
Monster Beverage
MNST • Vol: 15,284,847
Dell Technologies
DELL • Vol: 12,167,525

Top Losing Stocks

Mettler Toledo International
MTD • Vol: 539,266
Motorola Solutions
MSI • Vol: 3,101,643
Expedia
EXPE • Vol: 4,189,786
Coterra Energy
CTRA • Vol: 73,319,495
Fidelity National Information Services
FIS • Vol: 11,468,820